Flower pollen extract, sometimes referred to as "pollen extract" or "cernilton," has been studied for its role in managing prostatitis, specifically chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Several clinical trials and systematic reviews have explored its efficacy. The most notable scientific evidence comes from randomized, placebo-controlled trials that suggest flower pollen extract can improve symptoms such as pain, urinary difficulties, and quality of life in men with CP/CPPS. For instance, a 2006 meta-analysis (Wagenlehner et al., BJU International) concluded that pollen extract significantly improved prostatitis symptoms compared to placebo, although the number of high-quality studies was limited and study sizes were generally small. Proposed mechanisms include anti-inflammatory effects and modulation of smooth muscle tone in the prostate and bladder neck.

Despite these findings, the overall quality and quantity of evidence is moderate. Most studies have methodological limitations, such as small sample sizes, short duration, and risk of bias. The ingredient is not considered a standard first-line therapy, but it is recognized in some clinical practice guidelines as a possible adjunct treatment, especially for men who do not respond to conventional treatments. Importantly, the product is generally well tolerated with minimal side effects reported. While scientific evidence exists and supports its use to some extent, further large-scale, high-quality trials are needed to confirm efficacy and clarify mechanisms.